Seeking Alpha

Amgen (AMGN) is due to plead guilty today in an investigation into its business practices, the...

Amgen (AMGN) is due to plead guilty today in an investigation into its business practices, the U.S. attorney's office says, with the NYT reporting that the company will admit to mis-branding, which usually means promoting drugs for non-approved uses. Amgen will pay a fine close to the $780M it has set aside to cover the allegations, of which $150M will be for a criminal penalty.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)